Which company's drug is Erdafitinib, and what is its latest price?

Erdafitinib (Erdafitinib), a targeted therapy targeting FGFR gene mutations, has attracted widespread attention in the field of cancer treatment. With the advancement of science and technology and the continuous growth of market demand, the manufacturer pattern and price information of erdafitinib are undergoing continuous changes. This article will introduce you to the company developing erdafitinib and its latest selling price.

1. R&D company

The original developer and manufacturer of erdafitinib is Janssen Biotech, a subsidiary of Johnson & Johnson in the United States. As a leader in the industry, Johnson & Johnson has invested huge resources in the R&D and production of erdafitinib to ensure the high quality and significant efficacy of its drugs. At the same time, with the end of the patent protection period and the evolution of market demand, some generic drug manufacturers have also begun to get involved in the production of erdafitinib, such as Lucius Pharmaceuticals of Laos, ASEAN Pharmaceuticals, and Yaopin International of Bangladesh. These generic drug manufacturers meet the treatment needs of patients at more affordable prices while ensuring drug quality.

2. The latest price

The price of erdafitinib varies depending on the manufacturer, drug specifications, and sales channels. In developed countries such as the United States, the price of original erdafitinib is usually higher, which puts considerable financial pressure on patients. However, with the emergence of generic drugs and the continuous development of international trade, the price of erdafitinib is gradually becoming more reasonable.

Take Erdafitinib produced by Lucius Pharmaceuticals in Laos as an example. Its price has been significantly lower than that of the original drug. Currently, the Lao Lucius version of erdafitinib provides 3mg*28 tablets, 4mg*28 tablets, 5mg*28 tablets and other specifications for patients to choose from, with the price ranging from RMB 900 to more than 1,000 yuan.

In addition, it is worth noting that erdafitinib has not yet been officially launched in China, so it is not yet included in the medical insurance catalog. However, as the country’s emphasis on innovative drugs continues to increase, we have reason to believe that erdafitinib is expected to enter the Chinese market in the future and be included in the medical insurance catalog, thereby further reducing the financial burden on patients.

In summary, erdafitinib, as an important targeted therapy drug, plays a pivotal role in cancer treatment. As the number of manufacturers increases and prices decrease, erdafitinib will become more popular and affordable. At the same time, we look forward to the development and launch of more innovative drugs to bring more treatment options and hope to patients.